Skip to content
10-Q

Quarterly Report

Coherus Oncology, Inc. CHRS

0001104659-25-107852

← back to feed
Filed
Nov 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 31, 2025 120.87M sh
Shares Diluted Q3 2025 · Sep 30, 2025 116.23M sh
Shares Diluted Q3 2025 · Sep 30, 2025 116.06M sh
Shares Diluted Q3 2025 · Sep 30, 2024 115.21M sh
Shares Diluted restated Q3 2025 · Sep 30, 2024 114.26M sh
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$118.8M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$49.05M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $103.35M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $125.99M
Stockholders Equity Q3 2025 · Sep 30, 2025 $87.77M
Stockholders Equity Q3 2025 · Jun 30, 2025 $119.83M
Stockholders Equity Q3 2025 · Mar 31, 2025 −$183.47M
Stockholders Equity Q3 2025 · Dec 31, 2024 −$131.99M
Stockholders Equity Q3 2025 · Sep 30, 2024 −$87.97M
Stockholders Equity Q3 2025 · Jun 30, 2024 −$84.11M
Stockholders Equity Q3 2025 · Mar 31, 2024 −$81.84M
Stockholders Equity Q3 2025 · Dec 31, 2023 −$193.43M
Current Liabilities Q3 2025 · Sep 30, 2025 $372.3M
Current Liabilities Q3 2025 · Dec 31, 2024 $282.98M
Total Liabilities Q3 2025 · Sep 30, 2025 $428.75M
Total Liabilities Q3 2025 · Dec 31, 2024 $580.52M
Current Assets Q3 2025 · Sep 30, 2025 $460.96M
Current Assets Q3 2025 · Dec 31, 2024 $341.58M
Total Assets Q3 2025 · Sep 30, 2025 $516.52M
Total Assets Q3 2025 · Dec 31, 2024 $448.53M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.31
Eps Diluted Q3 2025 · Sep 30, 2025 $1.77
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.09
Eps Diluted restated Q3 2025 · Sep 30, 2024 $0.69
Eps Basic Q3 2025 · Sep 30, 2025 −$0.31
Eps Basic Q3 2025 · Sep 30, 2025 $1.77
Eps Basic Q3 2025 · Sep 30, 2024 −$0.09
Eps Basic Q3 2025 · Sep 30, 2024 $0.69
Sga Expense Q3 2025 · Sep 30, 2025 $24.93M
Sga Expense Q3 2025 · Sep 30, 2025 $77M
Sga Expense restated Q3 2025 · Sep 30, 2024 $28.13M
Sga Expense restated Q3 2025 · Sep 30, 2024 $95.87M
Rd Expense Q3 2025 · Sep 30, 2025 $27.25M
Rd Expense Q3 2025 · Sep 30, 2025 $77.91M
Rd Expense restated Q3 2025 · Sep 30, 2024 $22.05M
Rd Expense restated Q3 2025 · Sep 30, 2024 $71.07M
Net Income Q3 2025 · Sep 30, 2025 −$35.53M
Net Income Q3 2025 · Sep 30, 2025 $205.67M
Net Income Q3 2025 · Jun 30, 2025 $297.77M
Net Income Q3 2025 · Mar 31, 2025 −$56.57M
Net Income Q3 2025 · Sep 30, 2024 −$10.75M
Net Income Q3 2025 · Sep 30, 2024 $79.2M
Net Income Q3 2025 · Jun 30, 2024 −$12.92M
Net Income Q3 2025 · Mar 31, 2024 $102.88M
Operating Income Q3 2025 · Sep 30, 2025 −$44.33M
Operating Income Q3 2025 · Sep 30, 2025 −$135.25M
Operating Income restated Q3 2025 · Sep 30, 2024 −$46.86M
Operating Income restated Q3 2025 · Sep 30, 2024 −$154.27M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $3.72M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $9.77M
Cost Of Revenue restated Q3 2025 · Sep 30, 2024 $2.73M
Cost Of Revenue restated Q3 2025 · Sep 30, 2024 $5.98M